IQVIA Holdings Inc. $IQV Shares Bought by Aberdeen Group plc

Aberdeen Group plc boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 143,803 shares of the medical research company’s stock after acquiring an additional 5,960 shares during the period. Aberdeen Group plc’s holdings in IQVIA were worth $22,662,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Brighton Jones LLC raised its position in shares of IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares during the last quarter. GAMMA Investing LLC raised its position in shares of IQVIA by 56.3% in the first quarter. GAMMA Investing LLC now owns 2,197 shares of the medical research company’s stock valued at $387,000 after buying an additional 791 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of IQVIA by 34.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock valued at $2,338,000 after buying an additional 3,398 shares during the last quarter. Dynamic Advisor Solutions LLC raised its position in shares of IQVIA by 20.3% in the first quarter. Dynamic Advisor Solutions LLC now owns 1,770 shares of the medical research company’s stock valued at $312,000 after buying an additional 299 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its position in shares of IQVIA by 2.8% in the first quarter. Exchange Traded Concepts LLC now owns 5,357 shares of the medical research company’s stock valued at $944,000 after buying an additional 148 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on IQV. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 price objective on shares of IQVIA in a research report on Wednesday, September 3rd. Barclays boosted their price objective on shares of IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday, October 2nd. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the company from $195.00 to $235.00 in a report on Thursday. Finally, Truist Financial boosted their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $234.57.

IQVIA Price Performance

IQV opened at $203.95 on Tuesday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $237.34. The company has a 50 day moving average of $189.44 and a two-hundred day moving average of $168.30. The company has a market cap of $34.67 billion, a P/E ratio of 29.52, a P/E/G ratio of 2.18 and a beta of 1.32.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the previous year, the firm earned $2.64 earnings per share. IQVIA’s revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.